menu
    • menu
    [{"orgOrder":0,"company":"Ability Pharma","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ability Pharma \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ Cleveland Clinic"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ability Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"CTI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Ibrilatazar","moa":"||Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Ability Pharma \/ CTI Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ CTI Life Sciences"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"Hospital Clinic of Barcelona | Institut Catal\u00e0 d'Oncologia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I","graph3":"Ability Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ability Pharma \/ Hospital Clinic of Barcelona | Institut Catal\u00e0 d'Oncologia","highestDevelopmentStatusID":"6","companyTruncated":"Ability Pharma \/ Hospital Clinic of Barcelona | Institut Catal\u00e0 d'Oncologia"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"Hospital Vall d'Hebron | Institut Catal\u00e0 d'Oncologia | Hospital Cl\u00ednico Universitario de Valencia | Hospitales Universitarios Virgen del Roc\u00edo | Centre L\u00e9on B\u00e9rard | Institut Paoli-Calmettes | Gustave Roussy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ability Pharma \/ Hospital Vall d'Hebron | Institut Catal\u00e0 d'Oncologia | Hospital Cl\u00ednico Universitario de Valencia | Hospitales Universitarios Virgen del Roc\u00edo | Centre L\u00e9on B\u00e9rard | Institut Paoli-Calmettes | Gustave Roussy","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ Hospital Vall d'Hebron | Institut Catal\u00e0 d'Oncologia | Hospital Cl\u00ednico Universitario de Valencia | Hospitales Universitarios Virgen del Roc\u00edo | Centre L\u00e9on B\u00e9rard | Institut Paoli-Calmettes | Gustave Roussy"},{"orgOrder":0,"company":"AGC Pharma Chemicals Europe","sponsor":"Ability Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Pharma Chemicals Europe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Pharma Chemicals Europe \/ Ability Pharma","highestDevelopmentStatusID":"7","companyTruncated":"AGC Pharma Chemicals Europe \/ Ability Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Ibrilatazar

    Menu

    Ibrilatazar

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AGC Pharma Chemicals Europe

                            Spain
                            DCAT
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothYour reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

                            Lead Product(s) : Ibrilatazar

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Ability Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AGC Pharma and AbilityPharma to Produce Innovative Treatment for Pancreatic Cancer

                            Details : The collaboration aims for the development of an API for the treatment of pancreatic cancer, ABTL0812 (ibrilatazar), currently in clinical trials.

                            Product Name : ABTL0812

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : Ibrilatazar

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Ability Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ability Pharma

                            Spain arrow
                            Neuroscience
                            Not Confirmed

                            Ability Pharma

                            Spain arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibrilatazar,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : CTI Life Sciences

                            Deal Size : $7.6 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            AbilityPharma Raises €7M to Advance Phase 2b ABTL0812 for Metastatic Pancreatic Cancer

                            Details : AbilityPharma to obtain financing for the clinical development of ABTL0812 in combination with folfirinox. It is being evaluated in Phase I/II clinical trial studies for Metastatic Pancreatic Cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 11, 2024

                            Lead Product(s) : Ibrilatazar,Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : CTI Life Sciences

                            Deal Size : $7.6 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ability Pharma

                            Spain arrow
                            Neuroscience
                            Not Confirmed

                            Ability Pharma

                            Spain arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibrilatazar

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

                            Details : ABTL0812 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 16, 2020

                            Lead Product(s) : Ibrilatazar

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ability Pharma

                            Spain arrow
                            Neuroscience
                            Not Confirmed

                            Ability Pharma

                            Spain arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibrilatazar

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Cleveland Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ABTL0812 in Pancreatic Cancer

                            Details : ABTL0812 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2018

                            Lead Product(s) : Ibrilatazar

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Cleveland Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ability Pharma

                            Spain arrow
                            Neuroscience
                            Not Confirmed

                            Ability Pharma

                            Spain arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibrilatazar

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hospital Vall d'Hebron | Institut Català d'Oncologia | Hospital Clínico Universitario de Valencia | Hospitales Universitarios Virgen del Rocío | Centre Léon Bérard | Institut Paoli-Calmettes | Gustave Roussy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Efficacy and Safety of ABTL0812

                            Details : ABTL0812 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Endometrial Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 08, 2017

                            Lead Product(s) : Ibrilatazar

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hospital Vall d'Hebron | Institut Català d'Oncologia | Hospital Clínico Universitario de Valencia | Hospitales Universitarios Virgen del Rocío | Centre Léon Bérard | Institut Paoli-Calmettes | Gustave Roussy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ability Pharma

                            Spain arrow
                            Neuroscience
                            Not Confirmed

                            Ability Pharma

                            Spain arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibrilatazar

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Hospital Clinic of Barcelona | Institut Català d'Oncologia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I/Ib Clinical Trial of ABTL0812 in Advanced Cancer Patients

                            Details : ABTL0812 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 28, 2014

                            Lead Product(s) : Ibrilatazar

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Hospital Clinic of Barcelona | Institut Català d'Oncologia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth